- Product charge
- $165 / 30-day supply
- Bottle
- 15 mL
- Care access
- Book a visit with a Midi clinician
A product within Midi Custom Rx
Midi Health presents its NAD+ nasal spray as part of Midi Custom Rx, a range that also addresses skin, hair, sexual health and general wellness. The treatment begins with a Midi clinician evaluating the reader's history and symptoms. This is a prescribed offering within a care service rather than an ordinary supplement purchased without clinical review.
The product page links to booking a visit and says prescriptions are shipped directly from the service's formulary. We did not complete an appointment or evaluate a consultation. Our assessment concerns what the provider makes public and which details a prospective patient still needs in order to make a useful cost comparison.
A defined product charge, not a complete visit bill
Midi lists $165 for a thirty-day supply and identifies the container as 15 mL. Those two details make the product easier to describe than an unspecified starting offer. They also establish the denominator for a bottle comparison without requiring us to infer a package size from an illustration.
The product listing does not establish that $165 includes the consultation or any other services a particular patient may need. Do not assume that a clinical visit's insurance arrangements, if available, also cover this prescription. Ask Midi to distinguish visit charges, the medication charge, shipping terms and any follow-up costs on the actual estimate.
Prescribing and product details still matter
A stated volume does not reveal concentration. Fifteen milliliters describes the amount of liquid in a bottle; it does not tell a reader the total amount of NAD+ or the amount dispensed by an individual spray. Those details should come from the prescribed product's pharmacy label, not an online cost calculation.
Confirm the dispensing pharmacy, whether the preparation is compounded, storage instructions and the date after which it should no longer be used. The provider's thirty-day description is a commercial supply statement. It should not be substituted for individualized instructions or treated as a reason to continue a product a clinician has told you to stop.
The promise and its evidence boundary
Midi markets the spray around energy and mental clarity, with language distinguishing it from caffeine or other stimulants. NAD+ does have an important biological role, but that fact cannot establish how well this particular nasal preparation works for a patient's symptoms. We did not verify a controlled trial of the finished Midi spray.
Similarly, a clinician evaluating someone with midlife symptoms should not be equated with proof that every symptom arises from reduced NAD+. Ask what the proposed treatment is meant to address, what alternatives exist and what outcome would justify continuing. Prescription access and clinical effectiveness are separate questions in this review.
A useful next step for comparison shoppers
Midi belongs on a shortlist when the reader wants to discuss a clearly priced nasal bottle within an existing clinical relationship. The strength of the public listing is its explicit supply period and volume. The main gap is the complete cost of obtaining and maintaining that prescription through the care pathway.
Request an estimate for the first appointment and first bottle, then ask what the next refill requires. Keep those answers alongside another provider's equivalent quote. Comparing the finished plan, rather than treating $165 as an all-inclusive service subscription, produces a more accurate budget and a better set of questions for the clinician.
Useful distinctions
- Explicit thirty-day supply and 15 mL bottle
- Clinician assessment described
- Dedicated Custom Rx product page
Limitations to weigh
- Visit and medication costs need separate confirmation
- Strength is not established by bottle volume
- Product-specific clinical trial not verified
Sources & further reading
Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.